Skip to content

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06337305
Enrollment
74
Registered
2024-03-29
Start date
2020-08-19
Completion date
2023-08-19
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Brief summary

This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies.

Detailed description

This is a prospective cross-sectional survey-based study composed of both a retrospective chart review and 3-series patient survey. This study will help elicit potential areas throughout the perioperative course of radical cystectomy to improve patient resilience and quality of life, providing opportunity for future interventional studies. Primarily, the study will evaluate health related quality of life and resiliency in patients throughout the perioperative course of a radical cystectomy for bladder cancer. The primary objective will be the correlation of the Connor-Davidson Resilience Scale (CD-RISC-25) and the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-BL-Cys) score. Patients will be identified and undergo consent and baseline assessments, including completion of surveys prior to their cystectomy. A retrospective chart review will also be completed to record information regarding patient's cancer stage, treatment status, diagnosis date, insurance type, and related medical conditions and medications. Data from retrospective chart review will be collected and recorded in a secure REDCap database for all eligible patients. Subsequent surveys will be administered again at approximately 10-30 days postoperatively, as well as 60-120 days postoperatively.

Interventions

None listed

Sponsors

University of Kansas Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with a diagnosis of bladder cancer * Patients electing to undergo radical cystectomy as treatment * ≥ 18 years of age * Able to speak and read English * Willing and able to provide informed consent * Functioning telephone number or access to one

Exclusion criteria

* Patients opting to not undergo radical cystectomy * Minors

Design outcomes

Primary

MeasureTime frameDescription
Change in resiliency as measured by the Connor-Davidson Resilience Scale (CD-RISC-25).Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operativeThe Connor-Davidson Resilience scale is a 25-item self-administered instrument for assessing resilience that is consistent in a variety of populations, including clinical and community. Scoring: 0-100 (sum total of all items, each of which is scored 0-4). Higher score reflects greater resilience.
Change in quality of life in patients undergoing radical cystectomy as measured by the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-Bl-Cys).Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operativeThe FACT-BL-Cys is a condition-specific instrument for patients undergoing radical cystectomy to measure quality of life. Scoring: 0-168 (sum total of all items). Higher score reflects better health-related quality of life.
Change in quality of life in patients undergoing radical cystectomy as measured by the PROMIS-29.Prior to radical cystectomy, 10-30-days post-operative, and 90-days (+/-30-days) post-operativeThe PROMIS-29 is a disease non-specific measure of pain intensity using a 1-5 rating and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance). Scoring: High scores mean more of the concept being measured.

Secondary

MeasureTime frameDescription
DemographicsBaseline to 90-days (+/-30 days) post-operativeCharacterize trends that correspond with greater levels of resiliency and quality of life
Identification of clinical and demographic factors in bladder cancer patientsBaseline to 90-days (+/-30 days) post-operativeIdentify clinical and demographic factors related to higher post-cystectomy resiliency in patients with bladder cancer.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026